New Drug Upends Kidney Treatment Playbook

A doctor's gloved hand placing red blocks with health symbols on a table

A kidney drug already proven to protect diabetic patients just cleared a massive hurdle that could put it in front of tens of millions of people who never had diabetes at all.

Story Snapshot

Finerenone, originally approved for chronic kidney disease in type 2 diabetes patients, has now shown it can slow kidney disease progression in non-diabetic patients as well.
The pivotal FIND-CKD phase 3 trial met its primary endpoint, with finerenone significantly delaying kidney disease progression versus placebo in non-diabetic chronic kidney disease patients.
Separate trial results also show finerenone reduces kidney damage markers in type 1 diabetes patients, further expanding the drug’s potential reach.
Experts caution that while the signals are strong, full peer-reviewed outcomes data for non-diabetic populations are still pending, and the current non-diabetic evidence rests largely on sponsor-reported top-line results.

The Drug That Started With One Patient Group and May Redefine Treatment for Millions More

Chronic kidney disease affects roughly one in seven American adults, and for most of its history, treatment options have been frustratingly limited. Finerenone, a drug that blocks a hormone receptor linked to kidney scarring and inflammation, entered the scene with solid credentials in diabetic kidney disease. The landmark FIDELIO-DKD trial published in the New England Journal of Medicine demonstrated that finerenone produced meaningfully lower risks of kidney disease progression and cardiovascular events compared to placebo in patients with chronic kidney disease and type 2 diabetes. ^[2] That was the foundation. What happened next is the more interesting story.

Researchers and drug developers began asking an obvious question: if finerenone disrupts the biological pathway that drives kidney damage in diabetic patients, why would that same pathway behave differently in non-diabetic patients? The mineralocorticoid receptor, which finerenone blocks, drives inflammation and fibrosis in kidney tissue regardless of whether the patient has diabetes. ^[5] That biological logic pushed the science toward broader testing, and the results are now arriving fast enough to change clinical thinking.

The FIND-CKD Trial Changes the Conversation on Non-Diabetic Kidney Disease

The FIND-CKD trial is the first phase 3 trial to study finerenone specifically in patients with chronic kidney disease of non-diabetic origin, including those with hypertension-related kidney disease. ^[1] Bayer announced in early 2026 that the trial met its primary endpoint, with finerenone significantly delaying kidney disease progression versus placebo. ^[6] That announcement matters enormously because non-diabetic chronic kidney disease represents the majority of the chronic kidney disease population, a group that has historically had fewer targeted treatment options than their diabetic counterparts.

The caveat worth taking seriously is that what Bayer released is a top-line sponsor announcement, not yet a full peer-reviewed outcomes paper. ^[6] That distinction is not trivial. Drug development history is littered with promising press releases that looked different once independent scientists examined the complete dataset. The underlying science here is credible and the trial design was rigorous, but physicians and patients should understand that the full data picture is still emerging. Cautious optimism, grounded in the strength of the biological rationale and the clean trial design, is the appropriate posture right now.

Type 1 Diabetes Patients Now Have Evidence Too

The expansion of finerenone’s potential reach did not stop at non-diabetic kidney disease. The phase 3 FINE-ONE trial produced positive results showing that finerenone reduces urinary albumin-to-creatinine ratio, a standard measure of kidney damage, in people with chronic kidney disease and type 1 diabetes. ^[4] This is significant because type 1 diabetes patients were entirely absent from the original FIDELIO-DKD trial population. A drug that began its clinical journey in one diabetic subgroup is now demonstrating meaningful effects across diabetic and non-diabetic kidney disease categories simultaneously.

Presented today at #ERA2026, the INFINITY trial found that finerenone reduced the risk of chronic kidney disease progression, including kidney failure alone, and reduced heart failure hospitalisation, cardiovascular death, and all-cause death.

Explore the research:… pic.twitter.com/DzXa6gzMQ1

— The Lancet (@TheLancet) June 5, 2026

Surrogate endpoints like albumin-to-creatinine ratio and kidney filtration rate slope are not the same as hard outcomes like kidney failure or death, and that distinction matters in medicine. A meta-analysis of 66 randomized trials found a strong association between treatment effects on kidney filtration rate slope and long-term kidney outcomes, which is why researchers use these measures as reliable proxies. ^[1] The association is strong enough that regulators and clinicians treat improvements in these markers as meaningful evidence of benefit, even before the hardest endpoints fully mature over years of follow-up.

What This Means for the Roughly 37 Million Americans Living With Kidney Disease

The practical implication of finerenone’s expanding evidence base is that a drug once considered a specialized tool for a diabetic subgroup may become a frontline option across the full spectrum of chronic kidney disease. Finerenone has already demonstrated it slows diabetic kidney disease progression and reduces cardiovascular complications in that population. ^[5] If the full FIND-CKD peer-reviewed data confirm what the top-line results suggest, the treatment landscape for non-diabetic chronic kidney disease patients changes substantially. Nephrologists treating patients with hypertension-driven kidney damage, for example, would have a new evidence-backed option where few existed before. ^[1] The science is moving faster than most patients realize, and that is genuinely good news for a disease that has long outpaced its own treatment toolkit.